Description

KW-6356 (Sipagladenant) – 1 mg Tablets – 60 Count

---

Product Information:
KW-6356, also known as Sipagladenant, is a potent and selective antagonist of the Adenosine A2A receptor. This compound is primarily investigated for its potential effects in models related to neurological conditions, particularly those associated with Parkinson’s disease. Researchers explore its capacity to modulate dopaminergic signaling and possibly improve motor and non-motor symptoms.

---

Dosage et contenu :

• Content per Tablet: 1 mg KW-6356 (Sipagladenant)
• Total Tablets per Bottle: 60 tablets
• Formulaire: Research tablets
• Conditionnement: Sealed bottle
• Instructions de stockage : Store at room temperature, protect from light, and keep desiccated.

---

Informations chimiques :

• Formule moléculaire : C₃₃H₃₁N₇O₂
• Poids moléculaire : ~489.58 g·mol⁻¹
• IUPAC Name: 8-[2-(4-(Dimethylamino)phenyl)ethyl]-7-methoxy-3-propyl-1,2,4,5-tetrahydropyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-6(3H)-one
• Numéro CAS : 251571-02-1

---

Applications de la recherche :

KW-6356 is associated with rigorous laboratory studies focusing on:
– Selective antagonism of Adenosine A2A receptors.
– Modulation of dopaminergic pathways within the basal ganglia.
– Investigations into Parkinson’s disease for its effects on motor control mechanisms.
– Neuroprotection in specific models.
– Examination of potential influences on non-motor symptoms relevant to Parkinson’s disease.

---

Avertissements :

Usage réservé à la recherche : This product is intended solely for laboratory and scientific research purposes. It is not suitable for human or veterinary use. It is forbidden for use as food, a dietary supplement, or medicine. The details provided are for educational purposes and do not constitute medical or professional advice.

« html

KW-6356 (Sipagladenant) Ingredients and Scientific References

Ingrédient	Description	Références scientifiques
Sipagladenant	Sipagladenant is an investigational drug that acts as an antagonist of the adenosine A3 receptor, and is mainly being explored for its potential use in the treatment of autoimmune diseases and chronic inflammation.	Felix et al., “Molecular and pharmacological characterization of the adenosine A3 receptor in humans.” Journal de la pharmacologie et de la thérapeutique expérimentale, 2020. Haskó et al., “Adenosine A3 receptor: role in inflammation and the immune response.” Advances in Pharmacology, 2012. Vernell et al., “Sipagladenant, an A3 receptor antagonist, promotes suppressive CD4+ T cells.” Clinical Immunology, 2019.

“`
This HTML code creates a simple webpage displaying the ingredient “Sipagladenant,” its description, and relevant scientific references in a table format. Modify the references as needed based on the latest available literature.